Blog

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 11 • 8 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2022. “In the second quarter, we took important steps to advance our ongoing development programs, which was highlighted by the progression of our Phase 2b dose-optimization trial of…

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

Aug 11 • 2 min read

Today, FCM MM HOLDINGS, LLC announced that it has sent a letter to the Board of Directors of Mind Medicine Inc. (NASDAQ: MNMD) calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed’s at-the-money equity offering. FCM is directed and…

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Aug 11 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the conversion of a previously submitted provisional patent covering the biosynthetic production of methylated tryptamine derivatives including N,N-dimethyltryptamine and…

New Study Could Lead To Paradigm Shift In The Treatment of Depression

Aug 11 • 6 min read

It is comfortable to believe that science has all the answers and that our medical professionals are acting with a complete understanding of the human body and mind. However, even today when we know more about the world than ever, there is still much that is a mystery. Science, as a pursuit of knowledge and…

Red Light Holland 2022 Audited Year End Results – Bullish vs Bearish: Episode #5

Aug 11 • 1 min read

In this episode of Bullish vs Bearish, Adam Tubero talks about Red Light Holland‘s ($TRIP) 2022 audited year-end results and business highlights. Red Light Holland might be one of the most overlooked psychedelic companies in the sector. But is there a good reason for this? Watch the video below to find out. As always, you…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560